4-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)morpholine

Catalog No. :
ACJVLS037
CAS No. :
1201644-33-8
Molecular Formula :
C15H23BN2O3
Molecular Weight :
290.17

IUPAC Name:4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)morpholine

4-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)morpholine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg98%$133.00Login to see priceIn stockInquiry
250mg98%$245.00Login to see priceIn stockInquiry
1g98%$652.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)morpholine
IUPAC Name4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)morpholine
MDL No.MFCD13182159
Molecular FormulaC15H23BN2O3
Molecular Weight290.17
SMILESCC1(C)C(C)(C)OB(C2=CN=CC(N3CCOCC3)=C2)O1
InChI KeyITWSMAPMZRUIEU-UHFFFAOYSA-N
Synonym4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)pyridin-3-yl)morpholine;4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-pyridinyl]morpholine;Morpholine, 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-pyridinyl]-
CAS No.1201644-33-8
PubChem CID58412291

Synthetic Route by SureRoute

1. ACJVLS037 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACSYZJ539 route compound structure diagram
    ACSYZJ539865186-94-3 In Stock
  4. Then
  5. ACJVLS037 route product structure diagram
    ACJVLS0371201644-33-8 In Stock
Inquiry

2. ACJVLS037 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACPTOW753 route compound structure diagram
    ACPTOW753452972-13-3 In Stock
  4. Then
  5. ACJVLS037 route product structure diagram
    ACJVLS0371201644-33-8 In Stock
Inquiry

Comments (0)